Multiplexed immunofluorescence identifies high stromal CD68+PD-L1+ macrophages as a predictor of improved survival in triple negative breast cancer
Open Access
- 3 November 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-12
Abstract
Triple negative breast cancer (TNBC) comprises 10–15% of all breast cancers and has a poor prognosis with a high risk of recurrence within 5 years. PD-L1 is an important biomarker for patient selection for immunotherapy but its cellular expression and co-localization within the tumour immune microenvironment and associated prognostic value is not well defined. We aimed to characterise the phenotypes of immune cells expressing PD-L1 and determine their association with overall survival (OS) and breast cancer-specific survival (BCSS). Using tissue microarrays from a retrospective cohort of TNBC patients from St George Hospital, Sydney (n = 244), multiplexed immunofluorescence (mIF) was used to assess staining for CD3, CD8, CD20, CD68, PD-1, PD-L1, FOXP3 and pan-cytokeratin on the Vectra Polaris™ platform and analysed using QuPath. Cox multivariate analyses showed high CD68+PD-L1+ stromal cell counts were associated with improved prognosis for OS (HR 0.56, 95% CI 0.33–0.95, p = 0.030) and BCSS (HR 0.47, 95% CI 0.25–0.88, p = 0.018) in the whole cohort and in patients receiving chemotherapy, improving incrementally upon the predictive value of PD-L1+ alone for BCSS. These data suggest that CD68+PD-L1+ status can provide clinically useful prognostic information to identify sub-groups of patients with good or poor prognosis and guide treatment decisions in TNBC.Keywords
This publication has 69 references indexed in Scilit:
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 2015
- The treatment and survival of patients with triple negative breast cancer in a London populationSpringerPlus, 2014
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014Annals of Oncology, 2014
- Analysis and validation of tissue biomarkers for renal cell carcinoma using automated high-throughput evaluation of protein expressionHuman Pathology, 2014
- The clonal and mutational evolution spectrum of primary triple-negative breast cancersNature, 2012
- A clinically relevant gene signature in triple negative and basal-like breast cancerBreast Cancer Research, 2011
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Triple negative breast cancer - prognostic factors and survivalRadiology and Oncology, 2011
- Tumor-associated macrophages (TAM) as major players of the cancer-related inflammationJournal of Leukocyte Biology, 2009
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002